Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test

Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test

Organon said OG-6219 did not beat a placebo in a mid-stage clinical trial whose main goal was to measure the change in pelvic pain caused by endometriosis. The twice-daily pill came from Organon’s 2021 acquisition of Forendo Pharma. The post Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test appeared first on MedCity News.

Organon halts development of endometriosis pain drug after trial failure

Organon drug for endometriosis falls short in mid-stage study

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Organon discontinues endometriosis drug after Phase II flunk

Organon acquired the endometriosis drug in a $75m acquisition of Forendo Pharma in 2021.The post Organon discontinues endometriosis drug after Phase II flunk appeared first on Clinical Trials Arena.

Levi & Korsinsky Notifies Shareholders of Organon & Co. (OGN) of a Class Action Lawsuit and an Upcoming Deadline

Open the article to view the coverage from NewMediaWire

Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset

Plus, news about ArriVent BioPharma, Everest Medicines, Ribocure, Paradigm Biopharmaceuticals, Verrica and Torii: Organon discontinues experimental therapy for endometriosis-related pain: The Merck spinout said the drug did not meet the primary ...